APAC – the first targeted therapy for peripheral arterial occlusive disease.

Project Information

APAC-ON

Grant agreement ID: 190168043

DOI

10.3030/190168043

Project closed

EC signature date 28 October 2022

Start date 1 September 2022

End date 28 February 2025

Funded under

• The European Innovation Council (EIC)

Total cost

€ 2 999 125,00

EU contribution

€ 2 099 387,50

Coordinated by

APLAGON OY
Finland

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Websites, patent fillings, videos etc. (1)

Press release on Phase 2a clinical study results

Documents, reports (1)

Clinical study approval

Publications

Peer reviewed articles (5)

Pretreatment with a dual antiplatelet and anticoagulant (APAC) reduces ischemia–reperfusion injury in a mouse model of temporary middle cerebral artery occlusion—implications for neurovascular procedures

Author(s): Frederik Denorme, Juhana Frösen, Annukka Jouppila, Antti Lindgren, Julio C. Resendiz-Nieves, Hannu Manninen, Simon F. De Meyer, Riitta Lassila
Published in: Acta Neurochirurgica, Issue 166, 2024, ISSN 0942-0940
Publisher: Springer Science and Business Media LLC
DOI: 10.1007/s00701-024-06017-x

Treatment with APAC, a dual antiplatelet anticoagulant heparin proteoglycan mimetic, limits early collar-induced carotid atherosclerotic plaque development in Apoe−/− mice

Author(s): Ilze Bot, Lucie Delfos, Esmeralda Hemme, Mireia N.A. Bernabé Kleijn, Peter J. van Santbrink, Amanda C. Foks, Petri T. Kovanen, Annukka Jouppila, Riitta Lassila
Published in: Atherosclerosis, Issue 397, 2024, ISSN 0021-9150
Publisher: Elsevier BV
DOI: 10.1016/j.atherosclerosis.2024.118567

Antiplatelet-anticoagulant, APAC, a mimic of endogenous heparin, is an antithrombotic with von Willebrand factor-mediated characteristics

Author(s): Annukka Jouppila, Ilja Nevola, Marja Lemponen, Tomi Mattila, Riitta Lassila
Published in: Thrombosis Research, Issue 250, 2025, ISSN 0049-3848
Publisher: Elsevier BV
DOI: 10.1016/J.THROMRES.2025.109318

Thrombosis Research

Author(s): Nicole R. Bonetti, Annukka S. Jouppila, Seyed Soheil Saeedi, Saravi Brian C. Cooley, Lisa Pasterk, Luca L. Liberale, Sara Gobbato, Thomas F. Lüscher, Giovanni G. Camici, Riitta P. Lassila, Juerg H. Beer
Published in: Thrombosis Research, Issue Publication prior to print, 2023, ISSN 0049-3848
Publisher: Pergamon Press
DOI: 10.1016/j.thromres.2023.04.010

Heparin-like effect of a dual antiplatelet and anticoagulant (APAC) agent on red blood cell deformability and aggregation in an experimental model

Author(s): Adam Attila Matrai, Adam Varga, Barbara Bedocs-Barath, Erzsebet Vanyolos, Rita Orban-Kalmandi, Linda Loczi, Zsuzsa Bagoly, Annukka Jouppila, Riitta Lassila, Norbert Nemeth, Adam Deak
Published in: Journal of Thrombosis and Thrombolysis, 2024, ISSN 1573-742X
Publisher: Springer Science and Business Media LLC
DOI: 10.1007/s11239-024-03040-8